|
Alpha-synuclein structure, functions, and interactions
Fatemeh Nouri Emamzadeh
Division of Biomedical and Life Sciences, Faculty of Health and Medicine, University of Lancaster, Lancaster, LA1 4AY, United Kingdom
| Date of Submission | 20-Sep-2015 |
| Date of Decision | 03-Jan-2016 |
| Date of Acceptance | 24-Feb-2016 |
| Date of Web Publication | 09-May-2016 |
Correspondence Address:
Fatemeh Nouri Emamzadeh
Division of Biomedical and Life Sciences, Faculty of Health and Medicine, University of Lancaster, Lancaster, LA1 4AY
United Kingdom
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1735-1995.181989
At present, when a clinical diagnosis of Parkinson's disease (PD) is made, serious damage has already been done to nerve cells of the substantia nigra pars compacta. The diagnosis of PD in its earlier stages, before this irreversible damage, would be of enormous benefit for future treatment strategies designed to slow or halt the progression of this disease that possibly prevents accumulation of toxic aggregates. As a molecular biomarker for the detection of PD in its earlier stages, alpha-synuclein (α-syn), which is a key component of Lewy bodies, in which it is found in an aggregated and fibrillar form, has attracted considerable attention. Here, α-syn is reviewed in details. Keywords: Alpha-synuclein, biomarker, Parkinson′s disease
How to cite this article:
Emamzadeh FN. Alpha-synuclein structure, functions, and interactions. J Res Med Sci 2016;21:29 |
| Introduction | |  |
Human alpha-synuclein (α-syn) is predominantly expressed in the brain, especially in the neocortex, hippocampus, substantia nigra (SN), thalamus, and cerebellum, and is found in Lewy bodies (LBs). It is encoded by the SNCA that consists of 6 exons ranging in size from 42 to 1110 bp. [1],[2] Translation of SNCA starts from an autophagy-related start codon that is encoded by exon 2 and stops at a TAA stop codon that is encoded by exon 6. As noted above, the predominant form of α-syn is the full-length protein, but other shorter isoforms have also been described. In addition, C-terminal truncations of α-syn induce aggregation, suggesting that C-terminal modifications might be involved in the pathology of α-syn. [3] Changes in the levels of α-syn have been reported in cerebrospinal fluid and plasma of Parkinson's disease (PD) patients compared to control individuals. [4] Therefore, α-syn can be considered a potential biomarker for PD.
| Alpha-Synuclein Identification and Mapping | | |
In 1985, a neuron-specific protein of 143 amino acids (AA) was identified using an antibody against Torpedo californica purified cholinergic synaptic vesicles. Moreover, a 140-AA protein was also identified in a rat brain cDNA library with a high homology with the torpedo electric organ protein. The researchers concerned named the protein synuclein as they found it in both cytoplasmic and nuclear regions of neurons although later studies have never confirmed the nuclear localization of synuclein. Torpedo synucleins based on their molecular weights were classified in three major subclasses as 17.5 kDa, 18.5 kDa, and 20 kDa synucleins. The 17.5 kDa synuclein was predominantly expressed among other species. [5]
In a later study, amyloid protein from senile plaques of Alzheimer disease (AD) brain was analyzed, and this led to the identification of two other unknown peptides in addition to Aβ. Structural analysis of these proteins showed a high tendency for them to form β-structures. Therefore, it was hypothesized that these proteins, based on their hydrophobic identity and their ability to form β-structures, may act as a "seed" for Aβ aggregation. Therefore, Aβ protein as a consequence of interaction with these proteins might be converted into insoluble Aβ and trigger later neurodegenerative processes. These two unknown proteins were named non-Aβ components of AD amyloid (Non-Aβ component of AD plaques [NAC]). The concentration of both NAC proteins was the same in the amyloid fractions, and thus, it was suggested that they can both be cleaved from a single larger precursor. Later on, a 140-AA protein from a full-length encoding cDNA was identified as the precursor of NAC (NACP). NACP was detected in all tissues except liver with the highest concentration in the brain. These findings suggest a brain-specific role for NACP although it is expressed ubiquitously. [6]
Shortly afterward, 140-AA and 134-AA proteins that were present in the human brain in high amounts were purified and sequenced. Interestingly, the 140-AA protein was exactly the same as NACP, and it showed a high homology with torpedo and rat synuclein. Moreover, the 134-AA protein was identified as the human homolog of bovine phosphoneuroprotein 14 and showed 61% homology with the 140-AA protein. These findings suggested the existence of a family of human brain proteins, and the 140-AA protein was named α-syn while the 134-AA protein was named β-synuclein (β-syn). It was also shown that α-syn and β-syn are expressed predominantly in the brain and are concentrated in the presynaptic terminals of nerve cells. [7] Soon after, using FISH on human metaphase chromosomes, the chromosomal locations of SNCA and SNCB were identified. The results showed that α-syn is encoded by a gene on chromosome 4q21 and β-syn is encoded by a different gene located on chromosome 5q35. [8] Later, another type of synuclein was found to be expressed in high levels in ovarian and breast carcinomas. This was named γ-syn, and its gene was reported as breast cancer-specific gene 1. [9] Although γ-syn is also found in the peripheral nervous system, [10] its functional role is not completely understood.
| Alpha-Synuclein Structure | | |
α-Syn is a small acidic protein with three domains namely N-terminal lipid-binding α-helix, amyloid-binding central domain (NAC), and C-terminal acidic tail. α-Syn can be present as an α-helix structure in association with phospholipids or an unfolded conformation in the cytosol, suggesting that it plays specific roles in different cellular locations based on its dynamic structure. [11]
The N-terminal domain of α-syn (residues 1-87) is a positively charged region, including seven series of 11-AA repeats. Each 11-AA repeat contains a highly conserved KTKEGV hexameric motif that is also present in the α-helical domain of apolipoproteins. Moreover, the ability of α-syn to disrupt lipid bilayers is related to these repeat sequences. These repeats, via their ability to induce α-syn helical structure and subsequently reduce the tendency of α-syn to form β-structures, are important in α-syn-lipid interactions. [12]
The core region of α-syn (residues 61-95), also known as NAC, is involved in fibril formation and aggregation [13] as it can to form cross β-structures. [14]
The C-terminal domain of α-syn (residues 96-140) is an acidic tail of 43-AA residues, containing 10 Glu and 5 Asp residues. Structurally, the C-terminal domain of α-syn is present in a random coil structure due to its low hydrophobicity and high net negative charge. In vitro studies have revealed that α-syn aggregation can be induced by reduction of pH which neutralizes these negative charges. [15],[16] An interaction between the C-terminal domain and the NAC region of α-syn is thought to be responsible for inhibition of α-syn aggregation. Moreover, in the presence of Al 3+ , the C-terminal domain of α-syn binds to this metal ion and thus the ruined inhibitory effect of the C-terminal on NAC leads to α-syn aggregation. [17] The phosphorylation of residue serine 129 is important in the inhibitory property of the C-terminal region as dephosphorylation of serine 129 causes α-syn aggregation. [18] Moreover, the C-terminal of α-syn is homologous with small heat shock proteins (HSPs), suggesting a protective role for α-syn in keeping proteins out of the degradation process. [19]
| Alpha-Synuclein Structure and Lipid Interaction | | |
Discovering the fact that α-syn has the ability to interact with membrane lipids encouraged scientists to find out how this interaction is related to the biophysical features of lipids and α-syn. Therefore, in vitro studies were established using membrane mimics, with different acyl head groups, different fatty acid chains, and various degrees of saturation of fatty acyl chains. [20] Liposomes are spherical lipid bilayers with the head groups located either inside or outside of the sphere and the fatty acid tails concealed within the space between these two layers. Liposomes differ in size and lipid composition, and they usually are classified as small unilamellar vesicles (SUVs) with a diameter 10-100 nm, large unilamellar vesicles (LUVs) with a diameter 100 nm - 1 ΅m, and giant unilamellar vesicles (GUVs) with a diameter >1 μm. SUVs are good mimics for small secretory vesicles while GUVs can be good models for cellular membranes. [21]
α-Syn preferably binds to SUVs or LUVs containing negatively charged head groups. This interaction is mediated by the α-syn N-terminal region that is rich in lysine residues, suggesting that the α-syn N-terminal region preferentially binds to anionic lipids electrostatically. α-Syn also prefers some acidic head groups more than the others. For example, phosphatidylethanolamine, phosphatidic acid (PA), phosphatidylinositol, and ganglioside attract α-syn more than phosphatidylserine or phosphatidylglycerol. [21]
Moreover, polyunsaturated acyl chains can increase the ability of α-syn to interact with the membrane. This could be due to the larger space between poorly packed unsaturated lipids than compact saturated forms. In addition, the higher binding affinity of α-syn to SUVs and LUVs than GUVs may be related to the ability of α-syn to sense the membrane curvature. Disordered α-syn folds into an α-helical structure when it interacts with the membrane. This folding happens when α-syn inserts into hydrophobic acyl chains. Thus, α-syn has an elevated affinity for SUVs with a loose force between acyl chains due to high curvature. Taken together, these data indicate that α-syn has a preference for interaction with lipids and membranes containing unsaturated fatty acids with small anionic head groups and high curvature. [20]
Membrane-bound α-syn forms a helical structure that spans eleven residues in three distinct regions. A break at the middle of this structure divides α-syn into two helical zones, increasing its ability to bind to highly curved membranes. The α-syn A30P mutation shifts two of these turns and reduces the α-syn-lipid interaction strength. However, the α-syn A53T mutation seems not to affect α-syn conformation and interaction affinity [22] whereas E46K may increase the tendency of α-syn to interact with the membrane. [23]
Although the first 100 residues of α-syn are important for lipid interactions, different N-terminal regions of α-syn bind to membranes based on the lipid to protein ratio. Typically, α-syn binds to membranes with its first 25 AA residues (known as α-syn SL1 mode) when its ratio is high enough. However, reduction in the lipid to protein ratio causes α-syn to interact with the membrane with its SL2 mode which involves binding of the first 97 AA residues. [21]
The interaction of α-syn with the membrane may initiate its aggregation. Cytosolic α-syn does not aggregate unless membrane fractions are added to the experiment. Moreover, this aggregation produces protofibrillar α-syn that causes formation of open holes in the membrane. These open channels lead to leakage of neurotransmitter from synaptic vesicles and apoptosis due to mitochondrial membrane depolarization. Interestingly, deletion of α-syn residues 74-84 can stop aggregation. Thus, the central NAC, region of α-syn, with the ability to form β-sheet aggregates, seems to be responsible for membrane disruption. [24]
Thus, α-syn can interact with the negatively charged head groups of synthetic phospholipid vesicles. This interaction causes an alternation in the conformation of α-syn from a random coil to an α-helical pattern. The Asp98-Ala140 (C-terminal region) of α-syn that is rich in glutamate residues does not form the α-helical structure on interaction with vesicles and remains unstructured. Moreover, some studies suggest a protective role for α-syn on lipid membranes to prevent lipid oxidation. In addition, it has been found that α-syn interacts with multilamellar vesicles to produce of nonbilayer or small vesicles. Thus, α-syn may play a role in the organization of membrane lipid molecules. [21]
| Alpha-Synuclein Structure and Dynamics | | |
The dynamics of α-syn in cells can be modulated in different ways. A relationship between the N-terminal region of α-syn and α-syn cellular trafficking has been demonstrated by tracking α-syn within cells. Both A30P and A53T mutant α-syn increase its transition speed between the cytoplasm and the nucleus, suggesting that mutant α-syn shows enhanced transit to the nucleus compared to normal protein. Therefore, an elevated inhibitory effect of α-syn on chromatin acetylation may lead to cell death. The way that mutations alter α-syn dynamics is based on changes in α-syn secondary structure due to the mutations. For example, A30P mutant α-syn loses its membrane binding ability and thus locates to the nucleus in higher amounts than normal α-syn. [25] Phosphorylation of α-syn at S129 is another method for cells to control α-syn dynamics. Blocking of phosphorylation at S129 residue leads to the movement of nuclear α-syn to the cytoplasm, potentially followed by the formation of LB. [25]
| Alpha-Synuclein Functions | | |
The function of α-syn is not entirely understood, but the following functions appear to be consistent with some of this protein's activities. These functions are also summarized in [Table 1].
Suppression of apoptosis in dopaminergic neurons by reducing protein kinase C activity
Protein kinase C (PKC) is a serine-threonine kinase that phosphorylates different target proteins and therefore controls many mechanisms, such as apoptosis. This kinase is very sensitive to oxidative stress and triggers an apoptotic cascade in dopaminergic cells. α-Syn seems to be a PKC downregulator that can protect dopaminergic cells against apoptosis. Particularly, it has been shown that α-syn can switch off the proteolytic cascade by downregulation of PKCd expression. In dopaminergic cells, α-syn by deactivation of nuclear factor-kB reduces transcription of PKCd. Therefore, α-syn can be considered to be a neuroprotective protein in dopaminergic cells. [26]
Regulation of glucose levels
In addition to neurons, α-syn has also been identified in many other cell types, especially those involved in secretory processes. α-Syn decreases insulin secretion as a consequence of interaction with insulin-containing secretory granules. α-Syn interaction with K ATP channels of insulin-secretory granules leads to inhibition of insulin secretion triggered by glucose stimulation. These findings suggest a role for α-syn in diabetes that, as other degenerative disorders such as PD, is caused by a problem in the modulation of secretory processes. [27] Moreover, it has been shown that in type 2 diabetes (T2Ds), an amyloidogenic protein deposits in pancreatic β-cells and these patients are most likely to develop PD as α-syn may combine to amyloid fibrils and form irreversible damaging complexes in dopaminergic cells. [28] On the other hand, in a recent study, α-syn is shown to increase tissue glucose uptake and thus diminish insulin resistance and possibly T2D. This study shows that in both humans and mice, the higher levels of serum α-syn is directly associated with glucose metabolism. [29] It seems that α-syn can facilitate the entrance of glucose into adipose tissues and skeletal muscle through a G-protein-coupled receptor known as LPAR2-CD90. [30]
Modulation of calmodulin activity
Calcium-modulated protein, also known as calmodulin (CaM), is a messenger protein that can be activated through binding to Ca 2+ ions and triggers various mechanisms such as those involved in short- and long-term memory. It has been shown that both wild-type (WT) and mutant α-syn can interact with CaM not only in vitro but also in vivo. This interaction, which is dependent on calcium ions, causes α-syn fibrillization. Therefore, calcium ions can modulate α-syn function by inducing an interaction between α-syn and CaM. Moreover, CaM has an inhibitory effect on G-protein-coupled receptor kinase 5 (GRK5) in the absence of α-syn. On the other hand, CaM stimulates GRK5 activity in the presence of α-syn. Taken together, α-syn by controlling the conversion of CaM from an inhibitor to an activator, and vice versa, is involved in the modulation of GRK indirectly. [31]
Promotion of sensitive factor attachment protein receptor-complex assembly in vivo and in vitro
Neurotransmitters are secreted several times from presynaptic vesicles within 1 min. The sequential secretion pathway of the neurotransmitter is strongly related to the organized activity of membrane fusion proteins. Assembly and disassembly of the N-ethylmaleimide - sensitive factor attachment protein receptor (SNARE) complex is one of the reactions, which has to be repeated for each single neurotransmitter release cycle. However, assembly and disassembly of SNARE proteins are accompanied by the formation of intermediate SNARE protein structures that are unfolded and vulnerable to degeneration. α-Syn, by its chaperone activity, is involved in the maintenance of SNARE structure during these assembly/disassembly cycles. Specifically, direct interaction of α-syn with the SNARE -protein synaptobrevin-2/vesicle-associated membrane protein 2 causes the inhibition of SNARE complex assembly. Thus, α-syn dysfunction may lead to neurological problems because its deficiency reduces SNARE complex assembly. [32] During the SNARE complex assembly, unfolded cytosolic α-syn monomers bind to presynaptic membranes and form a complex of α-helically folded α-syn homomers, that is, chaperones assembly of SNARE complex and lead to neuroprotection in presynaptic terminals. [33] Moreover, large oligomers of α-syn unlike monomers are harmful, and bind to an N-terminal domain of a specific SNARE protein called synaptobrevin-2 and prevent assembly of SNARE complex leading to neurodegeneration. [34]
Acting as a molecular chaperone
α-Syn is considered to be a chaperone protein because it contains regions that are homologous with 14-3-3 proteins that interact with many cellular proteins. 14-3-3 proteins are members of the cytoplasmic chaperone family that phosphorylate the binding site of their targets, including PKC, Bcl-2-associated death promoter (BAD), and Extracellular-signal-regulated kinases (ERK). It has been shown that α-syn can also bind to the targets of 14-3-3. In addition, overexpression of α-syn under thermal and chemical conditions that prevent aggregation of target proteins is another reason for suggesting α-syn as a chaperone. α-Syn chaperone activity is dependent on both its N- and C-terminal regions. The N-terminal domain is responsible for α-syn interaction with substrate proteins, leading to the formation of a large complex while the C-terminal domain is responsible for the solubilization of that complex. [35]
The HSPs are also a family of chaperone proteins that are expressed in response to cellular stresses. HSPs are involved in stabilizing proteins to obtain correct conformations, refolding of incorrect protein structures, and degradation of misfolded proteins. It has been shown that α-syn is part of a chaperone complex containing Hsc70/Hsp70 and two co-chaperones that are responsible for efficient neurotransmitter release. [36] The functional link between α-syn and HSPs is also examined in an experiment that the csp gene was deleted in knockout (KO) mice. CSPα as an HSP is recruited into the outer membrane of presynaptic vesicles and plays role in neurotransmitter release. Deletion of this protein is associated with the reduction of α-syn levels and lethal neurodegeneration. Interestingly, CSPα KO mice can be rescued from death if human WT α-syn was overexpressed that shows how α-syn can recover a chaperone activity. [37]
Maintenance of polyunsaturated fatty acids levels
The brain as the second main source of lipid content after adipose tissue is enriched in two polyunsaturated fatty acids (PUFAs), arachidonic acid and docosahexaenoic acid, which constitute about 20% of the brain fatty acids. Acyl-coA synthetase (ACSL) by adding acyl groups to a fatty acid backbone synthesizes these fatty acids from other available fatty acid stocks. The ACSL6 isoform that incorporates arachidonic acid into phospholipids is modulated by α-syn. Therefore, α-syn may be involved in the presentation of substrates to ACSL and consequently, in control of the brain's PUFAs levels. [38]
Acting as an antioxidant and preventing oxidation of unsaturated lipids in vesicles
Oxidative stress in dopaminergic neurons could initiate the pathological damage leading to PD. This damage is triggered by oxidation of unsaturated phospholipids that consequently damage both cellular and intracellular membranes. The sensitivity of dopaminergic neurons to such damage is caused by the oxidative metabolism of dopamine within these cells. Therefore, dopaminergic cell membranes that are rich in unsaturated fatty acids are more vulnerable to this oxidation and damage. The monomeric form of α-syn by interaction with lipid membranes can protect lipids from oxidation, but the fibrillar form of α-syn does not have this capability. Therefore, it seems that monomeric α-syn could act as an antioxidant that plays an important role in dopaminergic neurons to protect them against oxidative damage. [39] Another study suggests that maybe α-syn is not an antioxidant but can prevent apoptosis by binding to cytochrome c oxidase in mitochondrial membrane and inhibits release of cytochrome c from mitochondria to cytosol. Consequently, caspases cannot be activated and thus cannot trigger apoptosis. [40] Moreover, hydrogen peroxide cannot damage α-syn expressing neural cells while it is toxic in control cells. Hydrogen peroxide in the absence of α-syn activates c-Jun N-terminal kinase (JNK), a member of mitogen-activated protein kinase (MAPK) family that promotes apoptosis under oxidative stress condition. α-Syn by activation of JNK-interacting protein/islet-brain (JIP-1b/IB1) as an inhibitor of JNK pathway may protect cells from injury. [41]
Neuronal differentiation
As α-syn is both functionally and structurally homologous with chaperone protein 14-3-3, [42] it can interact not only with 14-3-3 itself but also with its ligands, such as kinase suppressor of Ras. Therefore, α-syn is considered to be involved in different cellular functions via activation of Ras. The activated form of Ras can activate a chain of events including the ERK/MAPK pathway that is involved in sending a growth factor signal from the cell receptor to transcription factors in the nucleus. [43] Moreover, α-syn binds to membrane via interaction by Ras-related GTPase Rab3a. This molecular association is evidenced using antibody against Rab3a that dissociates bound α-syn from membrane signifying that Rab3a is involved in stabilizing α-syn on synaptosomes. [44]
Regulation of dopamine biosynthesis
α-Syn as a downregulator of tyrosine hydroxylase (TH) activity can modulate production of dopamine and control its cellular levels. Therefore, α-syn-reduced expression or α-syn aggregation leads to increased dopamine synthesis, leading to oxidative stress caused by dopamine metabolism. The inhibitory effect of α-syn on TH activity is not direct and is dependent on the interaction between α-syn and protein phosphatase 2A (PP2A). This α-syn PP2A interaction activates PP2A phosphatase function, leading to dephosphorylation of TH-Ser 40 residue, and therefore TH inhibition. Both α-syn overexpression and mutations have been shown to upregulate the inhibitory effect of α-syn on TH and dopamine levels, leading to downregulation of dopamine synthesis and release. [45] On the other hand, it has been shown that overexpression of α-syn increases activity of src, a member of nonreceptor tyrosine kinases family, leading to hyperphosphorylation of proteins and neurodegeneration. Scr can phosphorylate PP2A as a substrate at Tyr 307 and consequently inhibit its phosphates activity. [46]
Modulating vesicle trafficking
The synaptic vesicle formation pathway starts with the curvation of the membrane into a bud with the help of coat proteins such as clathrin which act as a spherical frame. This process is followed by the targeting of vesicles to a specific secretory point with the help of SNARE proteins. In this pathway, α-syn binds to the curved membrane selectively to modulate vesicle trafficking in synapses. [47] α-Syn possibly reduces both the amount and the speed of vesicle recycling from synapses to the presynaptic area. This reduction in vesicular dynamics is important for synaptic homeostasis as the absence of α-syn disturbs; this equilibrium by increased vesicle trafficking. [48]
This modulating role of α-syn is because of its specific structure. The 11 residue repeats of α-syn in the presence of liposomes can fold to a membrane binding helix that is divided by a mid-unstructured fragment. [49] α-Syn can detect the vesicle pool as it has an affinity for lipid bilayers. This means that α-syn is more likely to be present at high levels in vesicle pools containing lots of small liposomes than in other parts of the cell since it can sense the membrane curvature of the vesicles. [50]
| Alpha-Synuclein-Protein Interactions and Parkinson Disease | | |
It is possible that α-syn could damage cells by interrupting the function of other proteins since it can interact with many proteins, including tubulin, [51] parkin, [52] phospholipases D (PLD), [53] tau protein, 14-3-3, and the dopamine receptor. [54]
Alpha-synuclein interaction with tubulin
α-Syn has been identified in combination with tubulin in PD brain extracts including LBs and Lewy neuritis. Moreover, in vitro studies have revealed that adding a small amount of tubulin in physiological media containing α-syn can be sufficient not only to start but also to accelerate α-syn aggregation into fibrils. [55] Furthermore, it has been shown that extracellular oligomeric α-syn can reduce polymerization of tubulins in dopaminergic neurons leading to cell death. [51] These findings suggest that in the brain, a similar interaction between tubulin and α-syn may be responsible for the formation of LBs. Therefore, it seems possible that environmental toxins could initiate α-syn aggregation by disrupting the assembly of tubulins into microtubules, leading to increased free cytosolic tubulins that can interact with α-syn.
Alpha-synuclein interaction with parkin
Parkin as the ubiquitin ligase member of the proteasome system is involved in the degradation of redundant and disordered proteins. Therefore, mutations in parkin by affecting its ligase activity could lead to the formation of insoluble aggregates. Parkin mutations that damage parkin function are the most common causes of familial PD in the form of autosomal recessive juvenile PD. It also seems possible that the interaction between α-syn and parkin in stress conditions forms a site for deposition of α-tubulin, and as a result, triggers alteration of the neuronal cytoskeleton, causing neuronal dysfunction. [52] Moreover, parkin and Leucine-rich repeat kinase2 (LRRK2) are two modulators of the secretory pathway, and they are assumed to be involved in the development of synapses. As regulation of synaptic vesicle dynamics is important for proper neuronal activity, both protein mutations could be related to synucleinopathy. [56]
Alpha-synuclein interaction with LRRK2
α-Syn as a presynaptic protein may accumulate in the cytosol when parkin and LRRK2 mutations destroy synaptic assemblies, leading to the unwanted distribution of α-syn in the cytosol. It has been shown that LRRK2 can affect α-syn trafficking as its overexpression destroys polymerization of tubulin. In addition, mutant LRRK2 may induce phosphorylation of α-syn at S129, propagating oligomerization. However, phosphorylation of α-syn is not due directly to LRRK2 activity or its interaction with α-syn. Possibly, 14-3-3 is a mediator between α-syn and LRRK2. Mitochondrial improper function and imperfect biogenesis are associated with mutant LRRK2, leading to the production of superoxide and subsequently aggregation of α-syn. Moreover, the ubiquitin-proteasome system activity and chaperone-mediated autophagy can be destroyed by either LRRK2 mutations or α-syn A53T mutation. Therefore, mutation of both proteins at the same time can even worsen the situation, leading to very high accumulation of proteins in neurons. [57]
Alpha-synuclein interaction with dopamine receptor
The dopamine transporter (DAT) is responsible for the reuptake of dopamine from the synapse and its delivery back to the presynaptic terminal of neurosecretory cells. It has been reported that, in PD brains, α-syn binds to the C-terminal region of DAT via its NAC sequence. This interaction increases neuronal levels of dopamine by facilitating the membrane clustering of DAT and enhancing its activity. Increased levels of dopamine in neurons can damage cells as a consequence of enhanced dopamine metabolism reactions leading to oxidative stress. [54] However, in normal brains, α-syn controls the neuronal levels of dopamine by decreasing DAT activity. These findings suggest that aggregated α-syn could be neurotoxic in dopaminergic cells by initiating exposure to free radical products of dopamine oxidative metabolism. [58]
Alpha-synuclein interaction with synphilin-1
An interaction between synphilin-1 and α-syn has been reported in vivo using the yeast two-hybrid system. [59] Moreover, α-syn and synphilin-1 aggregate into an eosinophilic cytosolic complex similar to LB in α-syn and synphilin-1 co-transfected mammalian cells. In normal conditions, the N-terminal domain of WT α-syn interacts with the central region (ankyrin and coiled-coil domains) of synphilin-1. The sufficient regions for this interaction are α-syn AA 1-65 and synphilin-1 AA 349-555. This interaction protects α-syn from degradation by inhibition of 20S proteasome and thus formation of harmful aggregates in PD. [60] However, the α-syn A53T mutant interacts with synphilin-1 via its C-terminal domain, while the α-syn A30P mutant increases the number of α-syn synphilin-1 compounds. [61] Taken together, α-syn mutations could alter the site and efficiency of α-syn synphilin-1 interactions.
Alpha-Synuclein interaction with phospholipases
PLD is a hydrolytic enzyme that is located in the plasma membrane and hydrolyzes phosphatidylcholine to PA. PA, as a signaling lipid, modulates different processes, especially those involved in cellular morphology and vesicular transport. In neurons, PA may be involved in the growth, differentiation, and releases of neurotransmitters. α-Syn inhibits PLD activity. Therefore, α-syn, by controlling the production of PA, modulates cell signaling. [11] It has been shown that overexpression of PLD2 in rat brain leads to severe damage of dopaminergic neurons while either coexpression of human WT α-syn or reduction of PLD2 activity by siRNA inhibits the lethal effect of PLD2. Moreover, coimmunocapture of α-syn with PLD2 in the extract of striatal tissues revealed that α-syn interacts with PLD2 in vivo and downregulates its activity. [53]
Alpha-Synuclein interaction with small ubiquitin-related modifiers
Small ubiquitin-related modifiers usually attach to proteins and modify their structures after translation. This process, known as sumoylation, may help proteins to remain soluble. A study has shown that sumoylated α-syn does not aggregate, suggesting that sumoylation deficits could lead to α-syn accumulation. α-Syn residue lysine 96 and lysine 102 seem to be sites of sumoylation of α-syn. [62]
| Conclusion | | |
In PD brains, α-syn accumulates in nerve cells of the SN, pons, medulla, and gut leading to inflammation and cell death and subsequently difficulties in movement, digestion, circulation, and sleep. It seems that PD may be cured by stop α-syn from aggregation. Some pharmaceutical companies are focusing on compounds that prevent α-syn from aggregation such as NPT200-11 that is produced in Neuropore Company, and its human trial is begun. As α-syn is the most potential target for treatment of PD, many scientists around the world work on α-syn to know much more about its structure, functions, and interactions.
Acknowledgments
I would like to acknowledge Professor David Allsop. This work is supported by an EC Framework 7 Marie Curie Fellowship Training Network Grant (NEURASYNC) on "α-synuclein-related brain diseases."
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| References | | |
| 1. | McLean PJ, Kawamata H, Ribich S, Hyman BT. Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson′s disease-linked mutations. J Biol Chem 2000;275:8812-6.  |
| 2. | Yu S, Li X, Liu G, Han J, Zhang C, Li Y, et al. Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody. Neuroscience 2007;145:539-55. |
| 3. | Venda LL, Cragg SJ, Buchman VL, Wade-Martins R. α-synuclein and dopamine at the crossroads of Parkinson′s disease. Trends Neurosci 2010;33:559-68. |
| 4. | El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson′s disease. FASEB J 2006;20:419-25. |
| 5. | Maroteaux L, Campanelli JT, Scheller RH. Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 1988;8:2804-15. |
| 6. | Uéda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:11282-6. |
| 7. | Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett 1994;345:27-32. |
| 8. | Spillantini MG, Divane A, Goedert M. Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35. Genomics 1995;27:379-81. |
| 9. | Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, Godwin AK. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer 2000;88:2154-63. |
| 10. | George JM. The synucleins. Genome Biol 2001;reviews3002.1-reviews3002.6. |
| 11. | Ahn BH, Rhim H, Kim SY, Sung YM, Lee MY, Choi JY, et al. Alpha-synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells. J Biol Chem 2002;277:12334-42. |
| 12. | Sode K, Ochiai S, Kobayashi N, Usuzaka E. Effect of reparation of repeat sequences in the human α-synuclein on fibrillation ability. Biol Sci 2007;3:1-7. |
| 13. | Rajagopalan S, Andersen JK. Alpha synuclein aggregation: Is it the toxic gain of function responsible for neurodegeneration in Parkinson′s disease? Mech Ageing Dev 2001;122:1499-510. |
| 14. | Rodriguez JA, Ivanova MI, Sawaya MR, Cascio D, Reyes FE, Shi D, et al. Structure of the toxic core of α-synuclein from invisible crystals. Nature 2015;525:486-90. |
| 15. | Ahn M, Kim S, Kang M, Ryu Y, Kim TD. Chaperone-like activities of alpha-synuclein: Alpha-synuclein assists enzyme activities of esterases. Biochem Biophys Res Commun 2006;346:1142-9. |
| 16. | Hoyer W, Antony T, Cherny D, Heim G, Jovin TM, Subramaniam V. Dependence of alpha-synuclein aggregate morphology on solution conditions. J Mol Biol 2002;322:383-93. |
| 17. | Ly T, Julian RR. Protein-metal interactions of calmodulin and alpha-synuclein monitored by selective noncovalent adduct protein probing mass spectrometry. J Am Soc Mass Spectrom 2008;19:1663-72. |
| 18. | Esposito A, Dohm CP, Kermer P, Bähr M, Wouters FS. Alpha-synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton. Neurobiol Dis 2007;26:521-31. |
| 19. | Kim TD, Choi E, Rhim H, Paik SR, Yang CH. Alpha-synuclein has structural and functional similarities to small heat shock proteins. Biochem Biophys Res Commun 2004;324:1352-9. |
| 20. | Wang GF, Li C, Pielak GJ. 19F NMR studies of α-synuclein-membrane interactions. Protein Sci 2010;19:1686-91. |
| 21. | Pfefferkorn CM, Jiang Z, Lee JC. Biophysics of α-synuclein membrane interactions. Biochim Biophys Acta 2012;1818:162-71. |
| 22. | Ghosh D, Sahay S, Ranjan P, Salot S, Mohite GM, Singh PK, et al. The newly discovered Parkinson′s disease associated Finnish mutation (A53E) attenuates α-synuclein aggregation and membrane binding. Biochemistry 2014;53:6419-21. |
| 23. | Fredenburg RA, Rospigliosi C, Meray RK, Kessler JC, Lashuel HA, Eliezer D, et al. The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 2007;46:7107-18. |
| 24. | Högen T, Levin J, Schmidt F, Caruana M, Vassallo N, Kretzschmar H, et al. Two different binding modes of α-synuclein to lipid vesicles depending on its aggregation state. Biophys J 2012;102:1646-55. |
| 25. | Gonçalves S, Outeiro TF. Assessing the subcellular dynamics of alpha-synuclein using photoactivation microscopy. Mol Neurobiol 2013;47:1081-92. |
| 26. | Jin H, Kanthasamy A, Ghosh A, Yang Y, Anantharam V, Kanthasamy AG. α-synuclein negatively regulates protein kinase Cd expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity. J Neurosci 2011;31:2035-51. |
| 27. | Geng X, Lou H, Wang J, Li L, Swanson AL, Sun M, et al. α-synuclein binds the K (ATP) channel at insulin-secretory granules and inhibits insulin secretion. Am J Physiol Endocrinol Metab 2011;300:E276-86. |
| 28. | Sharma SK, Chorell E, Steneberg P, Vernersson-Lindahl E, Edlund H, Wittung-Stafshede P. Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner. Sci Rep 2015;5:12531. |
| 29. | Rodriguez-Araujo G, Nakagami H, Takami Y, Katsuya T, Akasaka H, Saitoh S, et al. Low alpha-synuclein levels in the blood are associated with insulin resistance. Sci Rep 2015;5:12081. |
| 30. | Rodriguez-Araujo G, Nakagami H, Hayashi H, Mori M, Shiuchi T, Minokoshi Y, et al. Alpha-synuclein elicits glucose uptake and utilization in adipocytes through the Gab1/PI3K/Akt transduction pathway. Cell Mol Life Sci 2013;70:1123-33. |
| 31. | Martinez J, Moeller I, Erdjument-Bromage H, Tempst P, Lauring B. Parkinson′s disease-associated alpha-synuclein is a calmodulin substrate. J Biol Chem 2003;278:17379-87. |
| 32. | Burré J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Südhof TC. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010;329:1663-7. |
| 33. | Burré J, Sharma M, Südhof TC. α-synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc Natl Acad Sci U S A 2014;111:E4274-83. |
| 34. | Choi BK, Choi MG, Kim JY, Yang Y, Lai Y, Kweon DH, et al. Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc Natl Acad Sci U S A 2013;110:4087-92. |
| 35. | Park SM, Jung HY, Kim TD, Park JH, Yang CH, Kim J. Distinct Roles of the N-terminal-binding Domain and the C-terminal-solubilizing Domain of á -Synuclein, a Molecular Chaperone. Biological Chemistry 2002;277:28512-20. |
| 36. | Witt SN. Molecular chaperones, α-synuclein, and neurodegeneration. Mol Neurobiol 2013;47:552-60. |
| 37. | Chandra S, Gallardo G, Fernández-Chacón R, Schlüter OM, Südhof TC. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005;123:383-96. |
| 38. | Ruipérez V, Darios F, Davletov B. Alpha-synuclein, lipids and Parkinson′s disease. Prog Lipid Res 2010;49:420-8. |
| 39. | Zhu M, Qin ZJ, Hu D, Munishkina LA, Fink AL. Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles. Biochemistry 2006;45:8135-42. |
| 40. | Latchoumycandane C, Anantharam V, Kitazawa M, Yang Y, Kanthasamy A, Kanthasamy AG. Protein kinase Cdelta is a key downstream mediator of manganese-induced apoptosis in dopaminergic neuronal cells. J Pharmacol Exp Ther 2005;313:46-55. |
| 41. | Hashimoto M, Hsu LJ, Rockenstein E, Takenouchi T, Mallory M, Masliah E. Alpha-synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells. J Biol Chem 2002;277:11465-72. |
| 42. | Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J, et al. Alpha-synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 1999;19:5782-91. |
| 43. | Fu H, Subramanian RR, Masters SC. 14-3-3 proteins: Structure, function, and regulation. Annu Rev Pharmacol Toxicol 2000;40:617-47. |
| 44. | Chen RH, Wislet-Gendebien S, Samuel F, Visanji NP, Zhang G, Marsilio D, et al. α-synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity. J Biol Chem 2013;288:7438-49. |
| 45. | Peng X, Tehranian R, Dietrich P, Stefanis L, Perez RG. Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J Cell Sci 2005;118(Pt 15):3523-30. |
| 46. | Yang W, Wang X, Duan C, Lu L, Yang H. Alpha-synuclein overexpression increases phospho-protein phosphatase 2A levels via formation of calmodulin/Src complex. Neurochem Int 2013;63:180-94. |
| 47. | Pranke IM, Morello V, Bigay J, Gibson K, Verbavatz JM, Antonny B, et al. α-synuclein and ALPS motifs are membrane curvature sensors whose contrasting chemistry mediates selective vesicle binding. J Cell Biol 2011;194:89-103. |
| 48. | Scott D, Roy S. α-synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. J Neurosci 2012;32:10129-35. |
| 49. | Varkey J, Isas JM, Mizuno N, Jensen MB, Bhatia VK, Jao CC, et al. Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins. J Biol Chem 2010;285:32486-93. |
| 50. | Drin G, Antonny B. Amphipathic helices and membrane curvature. FEBS Lett 2010;584:1840-7. |
| 51. | Chen L, Jin J, Davis J, Zhou Y, Wang Y, Liu J, et al. Oligomeric alpha-synuclein inhibits tubulin polymerization. Biochem Biophys Res Commun 2007;356:548-53. |
| 52. | Kawahara K, Hashimoto M, Bar-On P, Ho GJ, Crews L, Mizuno H, et al. Alpha-synuclein aggregates interfere with Parkin solubility and distribution: Role in the pathogenesis of Parkinson disease. J Biol Chem 2008;283:6979-87. |
| 53. | Gorbatyuk OS, Li S, Nguyen FN, Manfredsson FP, Kondrikova G, Sullivan LF, et al. α-synuclein expression in rat substantia nigra suppresses phospholipase D2 toxicity and nigral neurodegeneration. Mol Ther 2010;18:1758-68. |
| 54. | Lee FJ, Liu F, Pristupa ZB, Niznik HB. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J 2001;15:916-26. |
| 55. | Alim MA, Hossain MS, Arima K, Takeda K, Izumiyama Y, Nakamura M, et al. Tubulin seeds alpha-synuclein fibril formation. J Biol Chem 2002;277:2112-7. |
| 56. | Plowey ED, Chu CT. Synaptic dysfunction in genetic models of Parkinson′s disease: A role for autophagy? Neurobiol Dis 2011;43:60-7. |
| 57. | Liu G, Aliaga L, Cai H. α-synuclein, LRRK2 and their interplay in Parkinson′s disease. Future Neurol 2012;7:145-153. |
| 58. | Wersinger C, Sidhu A. Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci Lett 2003;340:189-92. |
| 59. | Engelender S, Kaminsky Z, Guo X, Sharp AH, Amaravi RK, Kleiderlein JJ, et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet 1999;22:110-4. |
| 60. | Alvarez-Castelao B, Castaño JG. Synphilin-1 inhibits alpha-synuclein degradation by the proteasome. Cell Mol Life Sci 2011;68:2643-54. |
| 61. | Neystat M, Rzhetskaya M, Kholodilov N, Burke RE. Analysis of synphilin-1 and synuclein interactions by yeast two-hybrid beta-galactosidase liquid assay. Neurosci Lett 2002;325:119-23. |
| 62. | Krumova P, Meulmeester E, Garrido M, Tirard M, Hsiao HH, Bossis G, et al. Sumoylation inhibits alpha-synuclein aggregation and toxicity. J Cell Biol 2011;194:49-60. |
[Table 1]
| This article has been cited by | | 1 |
Expression of a-Synuclein in the mouse retina is confined to inhibitory presynaptic elements |
|
| Qingwen Yang, Xin Lin, Jiayi Xiao, Wenhui Zhong, Fenglan Wang, Hang Tan, Bilin Rao, Jia Qu, Jun Zhang | | Journal of Comparative Neurology. 2023; | | [Pubmed] | [DOI] | | | 2 |
Sporadic SNCA mutations A18T and A29S exhibit variable effects on protein aggregation, cell viability and oxidative stress |
|
| Neha Joshi, Tanveera Rounaque Sarhadi, Atchaya Raveendran, Shirisha Nagotu | | Molecular Biology Reports. 2023; | | [Pubmed] | [DOI] | | | 3 |
Rotenone-Induced Model of Parkinson’s Disease: Beyond Mitochondrial Complex I Inhibition |
|
| María Teresa Ibarra-Gutiérrez, Norma Serrano-García, Marisol Orozco-Ibarra | | Molecular Neurobiology. 2023; | | [Pubmed] | [DOI] | | | 4 |
Polymorphic Alpha-Synuclein Oligomers: Characterization and Differential Detection with Novel Corresponding Antibodies |
|
| Kenya Moore, Urmi Sengupta, Nicha Puangmalai, Nemil Bhatt, Rakez Kayed | | Molecular Neurobiology. 2023; | | [Pubmed] | [DOI] | | | 5 |
Hybrids of polyphenolic/quinone acids, the potential preventive and therapeutic drugs for PD: Disaggregate a-Syn fibrils, inhibit inclusions, and repair damaged neurons in mice |
|
| Ming-Huan Lü, Zhen-Ping Wang, Li-Zi Xing, Wei Zhang, Feng Han, Guo-Long Huang, Wei Liu, Yun-Xiao Zhang, Ji Xu, Jinquan Cui | | European Journal of Medicinal Chemistry. 2023; 249: 115122 | | [Pubmed] | [DOI] | | | 6 |
Curcumin Modulates p62–Keap1–Nrf2-Mediated Autophagy in Rotenone-Induced Parkinson’s Disease Mouse Models |
|
| Aaina Singh Rathore, Saumitra Sen Singh, Hareram Birla, Walia Zahra, Priyanka Kumari Keshri, Hagera Dilnashin, Richa Singh, Shekhar Singh, Surya Pratap Singh | | ACS Chemical Neuroscience. 2023; | | [Pubmed] | [DOI] | | | 7 |
Mitochondrial Complex I as a Pathologic and Therapeutic Target for Parkinson’s Disease |
|
| Kamatham Pushpa Tryphena, Uppala Sai Nikhil, Poojitha Pinjala, Saurabh Srivastava, Shashi Bala Singh, Dharmendra Kumar Khatri | | ACS Chemical Neuroscience. 2023; | | [Pubmed] | [DOI] | | | 8 |
Fluorescence labeling methods influence the aggregation process of a-syn in vitro differently |
|
| S. Jadavi, S. Dante, L. Civiero, M. Sandre, L. Bubacco, L. Tosatto, P. Bianchini, C. Canale, A. Diaspro | | Nanoscale. 2023; | | [Pubmed] | [DOI] | | | 9 |
Dopaminergic Dysfunction Is More Symmetric in Dementia with Lewy Bodies Compared to Parkinson’s Disease |
|
| Tatyana Dmitrievna Fedorova, Karoline Knudsen, Jacob Horsager, Allan K. Hansen, Niels Okkels, Hanne Gottrup, Kim Vang, Per Borghammer | | Journal of Parkinson's Disease. 2023; : 1 | | [Pubmed] | [DOI] | | | 10 |
Single point mutations at the S129 residue of a-synuclein and their effect on structure, aggregation, and neurotoxicity |
|
| Esha Pandit, Lopamudra Das, Anoy Kumar Das, Sandip Dolui, Saumen Saha, Uttam Pal, Animesh Mondal, Joydeep Chowdhury, Subhas C. Biswas, Nakul C. Maiti | | Frontiers in Chemistry. 2023; 11 | | [Pubmed] | [DOI] | | | 11 |
The alleviative effect of Calendula officinalis L. extract against Parkinson’s disease-like pathology in zebrafish via the involvement of autophagy activation |
|
| Mengfei Wang, Haicheng Ye, Ping Jiang, Jibin Liu, Baokun Wang, Shanshan Zhang, Attila Sik, Ning Li, Kechun Liu, Meng Jin | | Frontiers in Neuroscience. 2023; 17 | | [Pubmed] | [DOI] | | | 12 |
SPEADI: Accelerated Analysis of IDP-Ion Interactions from MD-Trajectories |
|
| Emile de Bruyn, Anton Emil Dorn, Olav Zimmermann, Giulia Rossetti | | Biology. 2023; 12(4): 581 | | [Pubmed] | [DOI] | | | 13 |
Proteomics Methodologies: The Search of Protein Biomarkers Using Microfluidic Systems Coupled to Mass Spectrometry |
|
| Isabel De Figueiredo, Bernard Bartenlian, Guillaume Van der Rest, Antoine Pallandre, Frédéric Halgand | | Proteomes. 2023; 11(2): 19 | | [Pubmed] | [DOI] | | | 14 |
Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson’s disease |
|
| Hajung Yoo, Jeongmin Lee, Bokwang Kim, Heechang Moon, Huisu Jeong, Kyungmi Lee, Woo Jeung Song, Junho K. Hur, Yohan Oh | | BMB Reports. 2022; 55(7): 323 | | [Pubmed] | [DOI] | | | 15 |
The relationship of alpha-synuclein to mitochondrial dynamics and quality control |
|
| Naomi J. Thorne, David A. Tumbarello | | Frontiers in Molecular Neuroscience. 2022; 15 | | [Pubmed] | [DOI] | | | 16 |
Lysophospholipids: A Potential Drug Candidates for Neurodegenerative Disorders |
|
| Tatsuya Karaki, Hisao Haniu, Yoshikazu Matsuda, Tamotsu Tsukahara | | Biomedicines. 2022; 10(12): 3126 | | [Pubmed] | [DOI] | | | 17 |
Influence of Urea and Dimethyl Sulfoxide on K-Peptide Fibrillation |
|
| Jaroslaw Wawer, Jakub Karczewski, Robert Aranowski, Rafal Piatek, Danuta Augustin-Nowacka, Piotr Bruzdziak | | International Journal of Molecular Sciences. 2022; 23(6): 3027 | | [Pubmed] | [DOI] | | | 18 |
A Microplate-Based Approach to Map Interactions between TDP-43 and a-Synuclein |
|
| Angelo M. Jamerlan, Seong Soo A. An | | Journal of Clinical Medicine. 2022; 11(3): 573 | | [Pubmed] | [DOI] | | | 19 |
DNA methylation as a mediator of genetic and environmental influences on Parkinson’s disease susceptibility: Impacts of alpha-Synuclein, physical activity, and pesticide exposure on the epigenome |
|
| Samantha L. Schaffner, Michael S. Kobor | | Frontiers in Genetics. 2022; 13 | | [Pubmed] | [DOI] | | | 20 |
Proteomics Challenges for the Assessment of Synuclein Proteoforms as Clinical Biomarkers in Parkinson’s Disease |
|
| Marie-Laure Pons, Neil Loftus, Jerome Vialaret, Stephane Moreau, Sylvain Lehmann, Christophe Hirtz | | Frontiers in Aging Neuroscience. 2022; 14 | | [Pubmed] | [DOI] | | | 21 |
Protective Effects of Polysaccharides in Neurodegenerative Diseases |
|
| Yinying Wang, Rongsha Chen, Zhongshan Yang, Qian Wen, Xia Cao, Ninghui Zhao, Jinyuan Yan | | Frontiers in Aging Neuroscience. 2022; 14 | | [Pubmed] | [DOI] | | | 22 |
Potential biomarkers of addiction identified by real-time PCR in human peripheral blood lymphocytes: a narrative review |
|
| Shahrzad Nazari, Seyed Mahmoud Pourmand, Seyed Mohammad Makki, Serge Brand, Nasim Vousooghi | | Biomarkers in Medicine. 2022; | | [Pubmed] | [DOI] | | | 23 |
Metabolism and memory: a-synuclein level in children with obesity and children with type 1 diabetes; relation to glucotoxicity, lipotoxicity and executive functions |
|
| Nouran Yousef Salah, Sara Ibrahim Taha, Safeya Hassan, Mai Seif ElDin Abdeen, Mostafa Ahmad Hashim, Rana Mahmoud | | International Journal of Obesity. 2022; | | [Pubmed] | [DOI] | | | 24 |
Molecular Insights into the Misfolding and Dimerization Dynamics of the Full-Length a-Synuclein from Atomistic Discrete Molecular Dynamics Simulations |
|
| Yu Zhang, Ying Wang, Yuying Liu, Guanghong Wei, Feng Ding, Yunxiang Sun | | ACS Chemical Neuroscience. 2022; | | [Pubmed] | [DOI] | | | 25 |
Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review |
|
| Tyler S. Saunders, Danni A. Gadd, Tara L. Spires-Jones, Declan King, Craig Ritchie, Graciela Muniz-Terrera | | European Journal of Neuroscience. 2022; 56(9): 5650 | | [Pubmed] | [DOI] | | | 26 |
Mechanisms of NLRP3 activation and pathology during neurodegeneration |
|
| Sara Jose, Natalie J Groves, Kathrein E. Roper, Richard Gordon | | The International Journal of Biochemistry & Cell Biology. 2022; : 106273 | | [Pubmed] | [DOI] | | | 27 |
Liquid-liquid Phase Separation of a-Synuclein: A New Mechanistic Insight for a-Synuclein Aggregation Associated with Parkinson's Disease Pathogenesis |
|
| Semanti Mukherjee, Arunima Sakunthala, Laxmikant Gadhe, Manisha Poudyal, Ajay Singh Sawner, Pradeep Kadu, Samir K. Maji | | Journal of Molecular Biology. 2022; : 167713 | | [Pubmed] | [DOI] | | | 28 |
Effects of Mutations and Post-Translational Modifications on a-Synuclein In Vitro Aggregation |
|
| Samantha X. Pancoe, Yanxin J. Wang, Marie Shimogawa, Ryann M. Perez, Sam Giannakoulias, E. James Petersson | | Journal of Molecular Biology. 2022; : 167859 | | [Pubmed] | [DOI] | | | 29 |
Detection and assessment of alpha-synuclein in Parkinson disease |
|
| Hsien-Hao Tsao, Chung-Guei Huang, Yih-Ru Wu | | Neurochemistry International. 2022; : 105358 | | [Pubmed] | [DOI] | | | 30 |
Structural and mechanistic insights into modulation of a-Synuclein fibril formation by aloin and emodin |
|
| Vinod Kumar Meena, Vijay Kumar, Shivani Karalia, Rohit Sing Dangi, Monica Sundd | | Biochimica et Biophysica Acta (BBA) - General Subjects. 2022; : 130151 | | [Pubmed] | [DOI] | | | 31 |
a-Synuclein interacts differently with membranes mimicking the inner and outer leaflets of neuronal membranes |
|
| Samira Jadavi, Ester Canepa, Alberto Diaspro, Claudio Canale, Annalisa Relini, Silvia Dante | | Biochimica et Biophysica Acta (BBA) - Biomembranes. 2022; 1864(1): 183814 | | [Pubmed] | [DOI] | | | 32 |
Inhibition of Amyloid Protein Aggregation Using Selected Peptidomimetics |
|
| Debabrata Maity | | ChemMedChem. 2022; | | [Pubmed] | [DOI] | | | 33 |
Glycation of a-synuclein hampers its binding to synaptic-like vesicles and its driving effect on their fusion |
|
| Ana Belén Uceda, Juan Frau, Bartolomé Vilanova, Miquel Adrover | | Cellular and Molecular Life Sciences. 2022; 79(6) | | [Pubmed] | [DOI] | | | 34 |
Molecular insights into
a-synuclein
interaction with individual human core histones, linker histone, and
dsDNA |
|
| Sneha Jos,Hemanga Gogoi,Thazhe Kootteri Prasad,Manjunath A. Hurakadli,Neelagandan Kamariah,Balasundaram Padmanabhan,Sivaraman Padavattan | | Protein Science. 2021; | | [Pubmed] | [DOI] | | | 35 |
Toxic Feedback Loop Involving Iron, Reactive Oxygen Species, a-Synuclein and Neuromelanin in Parkinson’s Disease and Intervention with Turmeric |
|
| Zuné Jansen van Rensburg,Shameemah Abrahams,Soraya Bardien,Colin Kenyon | | Molecular Neurobiology. 2021; | | [Pubmed] | [DOI] | | | 36 |
Modulation of a-synuclein fibrillation by plant metabolites, daidzein, fisetin and scopoletin under physiological conditions |
|
| Ankita R. Rane,Harshad Paithankar,Ramakrishna V. Hosur,Sinjan Choudhary | | International Journal of Biological Macromolecules. 2021; | | [Pubmed] | [DOI] | | | 37 |
Biosensor approaches on the diagnosis of neurodegenerative diseases: Sensing the past to the future |
|
| Münteha Nur Sonuç Karaboga, SezginturkMustafa Kemal Sezgintürk | | Journal of Pharmaceutical and Biomedical Analysis. 2021; : 114479 | | [Pubmed] | [DOI] | | | 38 |
Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders |
|
| Dharmendra Kumar Khatri,Amey Kadbhane,Monica Patel,Shweta Nene,Srividya Atmakuri,Saurabh Srivastava,Shashi Bala Singh | | Current Research in Pharmacology and Drug Discovery. 2021; 2: 100022 | | [Pubmed] | [DOI] | | | 39 |
Mechanistic roles for altered O-GlcNAcylation in neurodegenerative disorders |
|
| Aaron T. Balana,Matthew R. Pratt | | Biochemical Journal. 2021; 478(14): 2733 | | [Pubmed] | [DOI] | | | 40 |
Prion-like C-Terminal Domain of TDP-43 and a-Synuclein Interact Synergistically to Generate Neurotoxic Hybrid Fibrils |
|
| Shailendra Dhakal,Courtney E. Wyant,Hannah E. George,Sarah E. Morgan,Vijayaraghavan Rangachari | | Journal of Molecular Biology. 2021; 433(10): 166953 | | [Pubmed] | [DOI] | | | 41 |
Ellagic Acid Modulates Uninduced as well as Mutation and Metal-Induced Aggregation of a-Synuclein: Implications for Parkinson’s Disease |
|
| Vinod Kumar Meena,Vijay Kumar,Shivani Karalia,Shivani Garima,Monica Sundd | | ACS Chemical Neuroscience. 2021; | | [Pubmed] | [DOI] | | | 42 |
PARkinsonæs: From cellular mechanisms to potential therapeutics |
|
| Zsofia Lengyel-Zhand,Laura N. Puentes,Robert H. Mach | | Pharmacology & Therapeutics. 2021; : 107968 | | [Pubmed] | [DOI] | | | 43 |
14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model |
|
| Rachel Underwood,Mary Gannon,Aneesh Pathak,Navya Kapa,Sidhanth Chandra,Alyssa Klop,Talene A. Yacoubian | | Acta Neuropathologica Communications. 2021; 9(1) | | [Pubmed] | [DOI] | | | 44 |
Beyond Neuronal Microtubule Stabilization: MAP6 and CRMPS, Two Converging Stories |
|
| Camille Cuveillier,Benoit Boulan,Charlotte Ravanello,Eric Denarier,Jean-Christophe Deloulme,Sylvie Gory-Fauré,Christian Delphin,Christophe Bosc,Isabelle Arnal,Annie Andrieux | | Frontiers in Molecular Neuroscience. 2021; 14 | | [Pubmed] | [DOI] | | | 45 |
Structural and Functional Changes of Reconstituted High-Density Lipoprotein (HDL) by Incorporation of a-synuclein: A Potent Antioxidant and Anti-Glycation Activity of a-synuclein and apoA-I in HDL at High Molar Ratio of a-synuclein |
|
| Kyung-Hyun Cho | | Molecules. 2021; 26(24): 7485 | | [Pubmed] | [DOI] | | | 46 |
The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson’s Disease: A Systematic Literature Review of Pre-Clinical Studies |
|
| Samay Prakash, Wayne G. Carter | | Brain Sciences. 2021; 11(12): 1573 | | [Pubmed] | [DOI] | | | 47 |
Interaction between Parkin and a-Synuclein in PARK2-Mediated Parkinson’s Disease |
|
| Daniel Aghaie Madsen,Sissel Ida Schmidt,Morten Blaabjerg,Morten Meyer | | Cells. 2021; 10(2): 283 | | [Pubmed] | [DOI] | | | 48 |
Sgt1 Regulates a-Synuclein Subcellular Localization and Expression of Parkinson’s Disease Related Genes, PINK1 and PARK9 |
|
| Anastasiia Bohush, Agnieszka Góral, Malgorzata Sierant, Barbara Nawrot, Wieslawa Lesniak, Anna Filipek | | Biomolecules. 2021; 11(11): 1675 | | [Pubmed] | [DOI] | | | 49 |
Biomarkers of Major Depressive Disorder: Knowing is Half the Battle |
|
| Sahil Malik,Ravinder Singh,Govind Arora,Akriti Dangol,Sanjay Goyal | | Clinical Psychopharmacology and Neuroscience. 2021; 19(1): 12 | | [Pubmed] | [DOI] | | | 50 |
A novel multi-target strategy to attenuate the progression of Parkinsonæs disease by diamine hybrid AGE/ALE inhibitor |
|
| N André Sasaki,Pascal Sonnet | | Future Medicinal Chemistry. 2021; | | [Pubmed] | [DOI] | | | 51 |
MicroRNAs, Parkinson’s Disease, and Diabetes Mellitus |
|
| Hsiuying Wang | | International Journal of Molecular Sciences. 2021; 22(6): 2953 | | [Pubmed] | [DOI] | | | 52 |
Further Characterization of Intrastriatal Lipopolysaccharide Model of Parkinson’s Disease in C57BL/6 Mice |
|
| Isaac Deng,Frances Corrigan,Sanjay Garg,Xin-Fu Zhou,Larisa Bobrovskaya | | International Journal of Molecular Sciences. 2021; 22(14): 7380 | | [Pubmed] | [DOI] | | | 53 |
Mechanistic Insight from Preclinical Models of Parkinson’s Disease Could Help Redirect Clinical Trial Efforts in GDNF Therapy |
|
| Karen M. Delgado-Minjares, Daniel Martinez-Fong, Irma A. Martínez-Dávila, Cecilia Bañuelos, M. E. Gutierrez-Castillo, Víctor Manuel Blanco-Alvarez, Maria-del-Carmen Cardenas-Aguayo, José Luna-Muñoz, Mar Pacheco-Herrero, Luis O. Soto-Rojas | | International Journal of Molecular Sciences. 2021; 22(21): 11702 | | [Pubmed] | [DOI] | | | 54 |
Oxidative stress factors in Parkinson’s disease |
|
| Jolanta Dorszewska,Marta Kowalska,Michal Prendecki,Thomas Piekut,Joanna Kozlowska,Wojciech Kozubski | | Neural Regeneration Research. 2021; 16(7): 1383 | | [Pubmed] | [DOI] | | | 55 |
From Seeds to Fibrils and Back: Fragmentation as an Overlooked Step in the Propagation of Prions and Prion-Like Proteins |
|
| Cristóbal Marrero-Winkens,Charu Sankaran,Hermann M. Schätzl | | Biomolecules. 2020; 10(9): 1305 | | [Pubmed] | [DOI] | | | 56 |
pH-Dependent Aggregation in Intrinsically Disordered Proteins Is Determined by Charge and Lipophilicity |
|
| Jaime Santos,Valentín Iglesias,Juan Santos-Suárez,Marco Mangiagalli,Stefania Brocca,Irantzu Pallarès,Salvador Ventura | | Cells. 2020; 9(1): 145 | | [Pubmed] | [DOI] | | | 57 |
Endosomal-Lysosomal Processing of Neurodegeneration-Associated Proteins in Astrocytes |
|
| Ching-On Wong | | International Journal of Molecular Sciences. 2020; 21(14): 5149 | | [Pubmed] | [DOI] | | | 58 |
Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers |
|
| André L. B. Bitencourt,Raquel M. Campos,Erika N. Cline,William L. Klein,Adriano Sebollela | | International Journal of Molecular Sciences. 2020; 21(23): 8920 | | [Pubmed] | [DOI] | | | 59 |
Linking Alpha-Synuclein to the Actin Cytoskeleton: Consequences to Neuronal Function |
|
| Marina I. Oliveira da Silva,Márcia A. Liz | | Frontiers in Cell and Developmental Biology. 2020; 8 | | [Pubmed] | [DOI] | | | 60 |
Intracellular Alpha-Synuclein and Immune Cell Function |
|
| Veselin Grozdanov,Karin M. Danzer | | Frontiers in Cell and Developmental Biology. 2020; 8 | | [Pubmed] | [DOI] | | | 61 |
Alpha-Synuclein Physiology and Pathology: A Perspective on Cellular Structures and Organelles |
|
| Luis D. Bernal-Conde,Rodrigo Ramos-Acevedo,Mario A. Reyes-Hernández,Andrea J. Balbuena-Olvera,Ishbelt D. Morales-Moreno,Rubén Argüero-Sánchez,Birgitt Schüle,Magdalena Guerra-Crespo | | Frontiers in Neuroscience. 2020; 13 | | [Pubmed] | [DOI] | | | 62 |
Cynomolgus Monkeys With Spontaneous Type-2-Diabetes-Mellitus-Like Pathology Develop Alpha-Synuclein Alterations Reminiscent of Prodromal Parkinson’s Disease and Related Diseases |
|
| Yan Sun,Chuang Guo,Lin Yuan,Wen Li,Zhan-You Wang,Feng Yue,Jia-Yi Li | | Frontiers in Neuroscience. 2020; 14 | | [Pubmed] | [DOI] | | | 63 |
Looking Beyond the Core: The Role of Flanking Regions in the Aggregation of Amyloidogenic Peptides and Proteins |
|
| Sabine M. Ulamec,David J. Brockwell,Sheena E. Radford | | Frontiers in Neuroscience. 2020; 14 | | [Pubmed] | [DOI] | | | 64 |
Identifying the mechanisms of a-synuclein-mediated cytotoxicity in Parkinson’s disease: new insights from a bioinformatics-based approach |
|
| Sankha S Chakrabarti,Venkatadri S Sunder,Upinder Kaur,Sapna Bala,Priyanka Sharma,Manjari Kiran,Ravindra K Rawal,Sasanka Chakrabarti | | Future Neurology. 2020; : FNL49 | | [Pubmed] | [DOI] | | | 65 |
Using CRISPR-X for Optimization of Antibodies Towards A30P a-synuclein Oligomers in Immunotherapy of Parkinson’s Disease |
|
| Isabell C. Pitigoi, Courtney E. Ostromecki | | Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal. 2020; 4(7): 1 | | [Pubmed] | [DOI] | | | 66 |
Eye lens crystallin proteins inhibit the autocatalytic amyloid amplification nature of mature a-synuclein fibrils |
|
| Ricardo Gaspar,Tommy Garting,Anna Stradner,Peter Schuck | | PLOS ONE. 2020; 15(6): e0235198 | | [Pubmed] | [DOI] | | | 67 |
The Antiaggregative and Antiamyloidogenic Properties of Nanoparticles: A Promising Tool for the Treatment and Diagnostics of Neurodegenerative Diseases |
|
| Monika Pichla,Grzegorz Bartosz,Izabela Sadowska-Bartosz,Marco Malaguti | | Oxidative Medicine and Cellular Longevity. 2020; 2020: 1 | | [Pubmed] | [DOI] | | | 68 |
Alleviating toxic a-Synuclein accumulation by membrane depolarization: evidence from an in vitro model of Parkinson’s disease |
|
| Alysia Ross,Viktoria Xing,Ting Ting Wang,Samantha C. Bureau,Giovana A. Link,Teresa Fortin,Hui Zhang,Shawn Hayley,Hongyu Sun | | Molecular Brain. 2020; 13(1) | | [Pubmed] | [DOI] | | | 69 |
The contribution of Parkin, PINK1 and DJ-1 genes to selective neuronal degeneration in Parkinsonæs disease |
|
| Marc van der Vlag,Robbert Havekes,Pim R. A. Heckman | | European Journal of Neuroscience. 2020; | | [Pubmed] | [DOI] | | | 70 |
CSF a-synuclein correlates with CSF neurogranin in late-life depression |
|
| Davide Bruno,Chelsea Reichert Plaska,Daniel P. A. Clark,Henrik Zetterberg,Kaj Blennow,Marcel M. Verbeek,Nunzio Pomara | | International Journal of Neuroscience. 2020; : 1 | | [Pubmed] | [DOI] | | | 71 |
Demonstration of brain region-specific neuronal vulnerability in human iPSC-based model of familial Parkinson’s disease |
|
| Razvan-Marius Brazdis,Julian E Alecu,Daniel Marsch,Annika Dahms,Katrin Simmnacher,Sandra Lörentz,Anna Brendler,Yanni Schneider,Franz Marxreiter,Laurent Roybon,Beate Winner,Wei Xiang,Iryna Prots | | Human Molecular Genetics. 2020; | | [Pubmed] | [DOI] | | | 72 |
Unraveling the NaCl Concentration Effect on the First Stages of a-Synuclein Aggregation |
|
| Rafael Ramis,Joaquín Ortega-Castro,Bartolomé Vilanova,Miquel Adrover,Juan Frau | | Biomacromolecules. 2020; | | [Pubmed] | [DOI] | | | 73 |
Anti-Parkinsonæs disease activity of phenolic acids from Eucommia ulmoides Oliver leaf extracts and their autophagy activation mechanism |
|
| Shanshan Zhang,Zhangping Yu,Jingyu Xia,Xuanming Zhang,Kechun Liu,Attila Sik,Meng Jin | | Food & Function. 2020; | | [Pubmed] | [DOI] | | | 74 |
Aggregation of biologically important peptides and proteins: inhibition or acceleration depending on protein and metal ion concentrations |
|
| Benjamin Gabriel Poulson,Kacper Szczepski,Joanna Izabela Lachowicz,Lukasz Jaremko,Abdul-Hamid Emwas,Mariusz Jaremko | | RSC Advances. 2020; 10(1): 215 | | [Pubmed] | [DOI] | | | 75 |
Identification of on- and off-pathway oligomers in amyloid fibril formation |
|
| Alexander J. Dear,Georg Meisl,Andela Šaric,Thomas C. T. Michaels,Magnus Kjaergaard,Sara Linse,Tuomas P. J. Knowles | | Chemical Science. 2020; | | [Pubmed] | [DOI] | | | 76 |
Unravelling the effect of N(e)-(carboxyethyl)lysine on the conformation, dynamics and aggregation propensity of a-synuclein |
|
| Laura Mariño,Rafael Ramis,Rodrigo Casasnovas,Joaquín Ortega-Castro,Bartolomé Vilanova,Juan Frau,Miquel Adrover | | Chemical Science. 2020; 11(12): 3332 | | [Pubmed] | [DOI] | | | 77 |
Gut-Brain Axis in Parkinsonæs disease Etiology: The Role of Lipopolysaccharide |
|
| Dipita Bhattacharyya,Anirban Bhunia | | Chemistry and Physics of Lipids. 2020; : 105029 | | [Pubmed] | [DOI] | | | 78 |
Lipopolysaccharide Animal Models of Parkinson’s Disease: Recent Progress and Relevance to Clinical Disease |
|
| Isaac Deng,Frances Corrigan,Guangxi Zhai,Xin-Fu Zhou,Larisa Bobrovskaya | | Brain, Behavior, & Immunity - Health. 2020; : 100060 | | [Pubmed] | [DOI] | | | 79 |
Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease |
|
| David J. Marmion,Angela A. Rutkowski,Diptaman Chatterjee,Benjamin M. Hiller,Milton H. Werner,Erwan Bezard,Deniz Kirik,Thomas McCown,Steven J. Gray,Jeffrey H. Kordower | | Neurobiology of Disease. 2020; : 105184 | | [Pubmed] | [DOI] | | | 80 |
Remodeling microglia to a protective phenotype in Parkinson’s disease? |
|
| Ifeoluwa Oluleke Awogbindin,Ismail Ogunbayode Ishola,Marie-Kim St-Pierre,Micaël Carrier,Julie C. Savage,Thérèse Di Paolo,Marie-Ève Tremblay | | Neuroscience Letters. 2020; : 135164 | | [Pubmed] | [DOI] | | | 81 |
Overexpression of a-Synuclein Reorganises Growth Factor Profile of Human Astrocytes |
|
| Büsra Sengül,Erdinç Dursun,Alexei Verkhratsky,Duygu Gezen-Ak | | Molecular Neurobiology. 2020; | | [Pubmed] | [DOI] | | | 82 |
Mitochondrial Protein Import Dysfunction in Pathogenesis of Neurodegenerative Diseases |
|
| Shweta Goyal,Rajnish Kumar Chaturvedi | | Molecular Neurobiology. 2020; | | [Pubmed] | [DOI] | | | 83 |
Genetics of synucleins in neurodegenerative diseases |
|
| José Brás,Elizabeth Gibbons,Rita Guerreiro | | Acta Neuropathologica. 2020; | | [Pubmed] | [DOI] | | | 84 |
6-Hydroxydopamine: a far from simple neurotoxin |
|
| Damir Varešlija,Keith F. Tipton,Gavin P. Davey,Andrew G. McDonald | | Journal of Neural Transmission. 2020; | | [Pubmed] | [DOI] | | | 85 |
Using NMR spectroscopy to investigate the role played by copper in prion diseases |
|
| Rawiah A. Alsiary,Mawadda Alghrably,Abdelhamid Saoudi,Suliman Al-Ghamdi,Lukasz Jaremko,Mariusz Jaremko,Abdul-Hamid Emwas | | Neurological Sciences. 2020; | | [Pubmed] | [DOI] | | | 86 |
Selective vulnerability in a-synucleinopathies |
|
| Javier Alegre-Abarrategui,Katherine R. Brimblecombe,Rosalind F. Roberts,Elisavet Velentza-Almpani,Bension S. Tilley,Nora Bengoa-Vergniory,Christos Proukakis | | Acta Neuropathologica. 2019; | | [Pubmed] | [DOI] | | | 87 |
Plasma a
-synuclein levels are increased in patients with obstructive sleep apnea syndrome |
|
| Hao-Lun Sun,Bin-Lu Sun,Dong-Wan Chen,Yang Chen,Wei-Wei Li,Man-Yu Xu,Ying-Ying Shen,Zhi-Qiang Xu,Yan-Jiang Wang,Xian-Le Bu | | Annals of Clinical and Translational Neurology. 2019; | | [Pubmed] | [DOI] | | | 88 |
In-vitro and in-silico investigation of protective mechanisms of crocin against E46K a-synuclein amyloid formation |
|
| Marzieh Ghasemi Tigan,Arezou Ghahghaei,Milad Lagzian | | Molecular Biology Reports. 2019; | | [Pubmed] | [DOI] | | | 89 |
Prion Efficiently Replicates in a-Synuclein Knockout Mice |
|
| Edoardo Bistaffa,Martina Rossi,Chiara Maria Giulia De Luca,Federico Cazzaniga,Olga Carletta,Ilaria Campagnani,Fabrizio Tagliavini,Giuseppe Legname,Giorgio Giaccone,Fabio Moda | | Molecular Neurobiology. 2019; | | [Pubmed] | [DOI] | | | 90 |
The Role of Aptamer Loaded Exosome Complexes in the Neurodegenerative Diseases |
|
| Simranjeet Singh Sekhon,Gna Ahn,Ga-Young Park,Dae-Young Park,Sang-Hee Lee,Ji-Young Ahn,Yang-Hoon Kim | | Toxicology and Environmental Health Sciences. 2019; 11(2): 85 | | [Pubmed] | [DOI] | | | 91 |
Reprint of “Ganglioside lipids accelerate a-synuclein amyloid formation” |
|
| Ricardo Gaspar,Jon Pallbo,Ulrich Weininger,Sara Linse,Emma Sparr | | Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 2019; | | [Pubmed] | [DOI] | | | 92 |
Alpha synuclein in hematopoiesis and immunity |
|
| Yu Pei,Robert W. Maitta | | Heliyon. 2019; 5(10): e02590 | | [Pubmed] | [DOI] | | | 93 |
a-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinsonæs disease patients |
|
| Wojciech Paslawski,Justyna Zareba-Paslawska,Xiaoqun Zhang,Katharina Hölzl,Henrik Wadensten,Mohammadreza Shariatgorji,Shorena Janelidze,Oskar Hansson,Lars Forsgren,Per E. Andrén,Per Svenningsson | | Proceedings of the National Academy of Sciences. 2019; : 201821409 | | [Pubmed] | [DOI] | | | 94 |
A Coarse-Grained Molecular Dynamics Approach to the Study of the Intrinsically Disordered Protein a-Synuclein |
|
| Rafael Ramis,Joaquín Ortega-Castro,Rodrigo Casasnovas,Laura Mariño,Bartolomé Vilanova,Miquel Adrover,Juan Frau | | Journal of Chemical Information and Modeling. 2019; 59(4): 1458 | | [Pubmed] | [DOI] | | | 95 |
Mass Spectrometric Analysis of Lewy Body-Enriched a-Synuclein in Parkinson’s Disease |
|
| Payel Bhattacharjee,Annika Öhrfelt,Tammaryn Lashley,Kaj Blennow,Ann Brinkmalm,Henrik Zetterberg | | Journal of Proteome Research. 2019; | | [Pubmed] | [DOI] | | | 96 |
Recent advances of induced pluripotent stem cells application in neurodegenerative diseases |
|
| Nashwa Amin,Xiaoning Tan,Qiannan Ren,Ning Zhu,Benson O.A. Botchway,Zhiying Hu,Marong Fang | | Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2019; 95: 109674 | | [Pubmed] | [DOI] | | | 97 |
Deciphering the anti-Parkinson’s activity of sulphated polysaccharides from Chlamydomonas reinhardtii on the a-Synuclein mutants A30P, A53T, E46K, E57K and E35K |
|
| Gitanjali P Panigrahi,Ankita R Rane,Sirisha L Vavilala,Sinjan Choudhary | | The Journal of Biochemistry. 2019; | | [Pubmed] | [DOI] | | | 98 |
Upcoming diagnostic biomarkers with promising prospects in neurological disorders |
|
| Wasim Ahmad,Abuzer Ali,Amena Ali,Sana Khan,Saba Khan,Ibraheem Husain | | Clinical and Experimental Pharmacology and Physiology. 2019; | | [Pubmed] | [DOI] | | | 99 |
Physiological, molecular and genetic aspects of alpha-synuclein and its correlation with high alcohol consumption |
|
| Tania Yadira Martínez-Rodríguez,Mauricio Rey-Buitrago | | Revista de la Facultad de Medicina. 2019; 67(3): 315 | | [Pubmed] | [DOI] | | | 100 |
Early stages of Parkinson’s disease: aspects of the diagnosis and therapy |
|
| A. A. Pilipovich | | Medical Council. 2019; (18): 61 | | [Pubmed] | [DOI] | | | 101 |
Lipids at the Crossroad of a-Synuclein Function and Dysfunction: Biological and Pathological Implications |
|
| Natalia P. Alza,Pablo A. Iglesias González,Melisa A. Conde,Romina M. Uranga,Gabriela A. Salvador | | Frontiers in Cellular Neuroscience. 2019; 13 | | [Pubmed] | [DOI] | | | 102 |
Naphthoquinone Tryptophan Hybrids: A Promising Small Molecule Scaffold for Mitigating Aggregation of Amyloidogenic Proteins and Peptides |
|
| Guru KrishnaKumar Viswanathan,Ashim Paul,Ehud Gazit,Daniel Segal | | Frontiers in Cell and Developmental Biology. 2019; 7 | | [Pubmed] | [DOI] | | | 103 |
Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson’s Disease |
|
| Maria Zella,Judith Metzdorf,Friederike Ostendorf,Fabian Maass,Siegfried Muhlack,Ralf Gold,Aiden Haghikia,Lars Tönges | | Cells. 2019; 8(2): 105 | | [Pubmed] | [DOI] | | | 104 |
Prion and Prion-Like Protein Strains: Deciphering the Molecular Basis of Heterogeneity in Neurodegeneration |
|
| Carlo Scialò,Elena De Cecco,Paolo Manganotti,Giuseppe Legname | | Viruses. 2019; 11(3): 261 | | [Pubmed] | [DOI] | | | 105 |
Mechanical and thermodynamic properties of Aß42, Aß40, and a-synuclein fibrils: a coarse-grained method to complement experimental studies |
|
| Adolfo B Poma,Horacio V Guzman,Mai Suan Li,Panagiotis E Theodorakis | | Beilstein Journal of Nanotechnology. 2019; 10: 500 | | [Pubmed] | [DOI] | | | 106 |
Implications of alpha-synuclein nitration at tyrosine 39 in methamphetamine-induced neurotoxicity in vitro and in vivo |
|
| Hong-Hua Qiao,Lin-Nan Zhu,Yue Wang,Jia-Liang Hui,Wei-Bing Xie,Chao Liu,Ling Chen,Ping-Ming Qiu | | Neural Regeneration Research. 2019; 14(2): 319 | | [Pubmed] | [DOI] | | | 107 |
Clearing Extracellular Alpha-Synuclein from Cerebrospinal Fluid: A New Therapeutic Strategy in Parkinson’s Disease |
|
| Manuel Menéndez-González,Huber Padilla-Zambrano,Cristina Tomás-Zapico,Benjamin García | | Brain Sciences. 2018; 8(4): 52 | | [Pubmed] | [DOI] | | | 108 |
Insights into the Molecular Mechanisms of Alzheimer’s and Parkinson’s Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology |
|
| Orkid Coskuner-Weber,Vladimir Uversky | | International Journal of Molecular Sciences. 2018; 19(2): 336 | | [Pubmed] | [DOI] | | | 109 |
Comparing the Folds of Prions and Other Pathogenic Amyloids |
|
| José Flores-Fernández,Vineet Rathod,Holger Wille | | Pathogens. 2018; 7(2): 50 | | [Pubmed] | [DOI] | | | 110 |
Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors |
|
| Fatemeh N. Emamzadeh,Andrei Surguchov | | Frontiers in Neuroscience. 2018; 12 | | [Pubmed] | [DOI] | | | 111 |
Effect of rs3910105 in the Synuclein Gene on Dopamine Transporter Availability in Healthy Subjects |
|
| Youngduk Seo,Kyoungjune Pak,Hyun-Yeol Nam,Ju Won Seok,Myung Jun Lee,Eun-Joo Kim,Jae Meen Lee,Seong Jang Kim,In Joo Kim | | Yonsei Medical Journal. 2018; 59(6): 787 | | [Pubmed] | [DOI] | | | 112 |
Crucial role of protein oligomerization in the pathogenesis of Alzheimeræs and Parkinsonæs diseases |
|
| Minee L. Choi,Sonia Gandhi | | The FEBS Journal. 2018; | | [Pubmed] | [DOI] | | | 113 |
The Cellular Environment Affects Monomeric a-Synuclein Structure |
|
| Amberley D. Stephens,Maria Zacharopoulou,Gabriele S. Kaminski Schierle | | Trends in Biochemical Sciences. 2018; | | [Pubmed] | [DOI] | | | 114 |
Recent progress of drug nanoformulations targeting to brain |
|
| Abdur Rauf Khan,Xiaoye Yang,Manfei Fu,Guangxi Zhai | | Journal of Controlled Release. 2018; | | [Pubmed] | [DOI] | | | 115 |
Alpha-synuclein mitochondrial interaction leads to irreversible translocation and complex I impairment |
|
| Jimena H. Martínez,Federico Fuentes,Virginia Vanasco,Silvia Alvarez,Agustina Alaimo,Adriana Cassina,Federico Coluccio Leskow,Francisco Velazquez | | Archives of Biochemistry and Biophysics. 2018; 651: 1 | | [Pubmed] | [DOI] | | | 116 |
Post-translational modifications of Parkinsonæs disease-related proteins: Phosphorylation, SUMOylation and ubiquitination |
|
| Stella C. Junqueira,Eduarda G.Z. Centeno,Kevin A. Wilkinson,Helena Cimarosti | | Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2018; | | [Pubmed] | [DOI] | | | 117 |
The role of posttranslational modifications of a-synuclein and LRRK2 in Parkinsonæs disease: Potential contributions of environmental factors |
|
| Edward Pajarillo,Asha Rizor,Jayden Lee,Michael Aschner,Eunsook Lee | | Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2018; | | [Pubmed] | [DOI] | | | 118 |
Salt-bridge dynamics in intrinsically disordered proteins: A trade-off between electrostatic interactions and structural flexibility |
|
| Sankar Basu,Parbati Biswas | | Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 2018; 1866(5-6): 624 | | [Pubmed] | [DOI] | | | 119 |
Ganglioside lipids accelerate a-synuclein amyloid formation |
|
| Ricardo Gaspar,Jon Pallbo,Ulrich Weininger,Sara Linse,Emma Sparr | | Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 2018; 1866(10): 1062 | | [Pubmed] | [DOI] | | | 120 |
Cellular Proteostasis in Neurodegeneration |
|
| Alberim Kurtishi,Benjamin Rosen,Ketan S. Patil,Guido W. Alves,Simon G. Møller | | Molecular Neurobiology. 2018; | | [Pubmed] | [DOI] | | | 121 |
Formation of Heterotypic Amyloids: a-Synuclein in Co-Aggregation |
|
| Karishma Bhasne,Samrat Mukhopadhyay | | PROTEOMICS. 2018; : 1800059 | | [Pubmed] | [DOI] | | | 122 |
Alpha-Synuclein Toxicity on Protein Quality Control, Mitochondria and Endoplasmic Reticulum |
|
| Thaiany Quevedo Melo,Sjef J. C. V. M. Copray,Merari F. R. Ferrari | | Neurochemical Research. 2018; | | [Pubmed] | [DOI] | | | 123 |
Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson’s Disease-Relevant Phenotypes |
|
| S. L. Sison,S. C. Vermilyea,M. E. Emborg,A. D. Ebert | | Current Neurology and Neuroscience Reports. 2018; 18(12) | | [Pubmed] | [DOI] | | | 124 |
Role of Apolipoproteins and a-Synuclein in Parkinson’s Disease |
|
| Fatemeh Nouri Emamzadeh | | Journal of Molecular Neuroscience. 2017; | | [Pubmed] | [DOI] | | | 125 |
Ginkgolide K promotes the clearance of A53T mutation alpha-synuclein in SH-SY5Y cells |
|
| Wenbo Yu,Sheng Chen,Liang Cao,Jie Tang,Wei Xiao,Baoguo Xiao | | Cell Biology and Toxicology. 2017; | | [Pubmed] | [DOI] | | | 126 |
iPS cells in the study of PD molecular pathogenesis |
|
| Melanie M. Cobb,Abinaya Ravisankar,Gaia Skibinski,Steven Finkbeiner | | Cell and Tissue Research. 2017; | | [Pubmed] | [DOI] | | | 127 |
Bone loss in C57BL/6J-OlaHsd mice, a substrain of C57BL/6J carrying mutated alpha-synuclein and multimerin-1 genes |
|
| Tamar Liron,Bitya Raphael,Sahar Hiram-Bab,Itai A. Bab,Yankel Gabet | | Journal of Cellular Physiology. 2017; | | [Pubmed] | [DOI] | | | 128 |
DT-diaphorase Protects Against Autophagy Induced by Aminochrome-Dependent Alpha-Synuclein Oligomers |
|
| Patricia S. Muñoz,Juan Segura-Aguilar | | Neurotoxicity Research. 2017; | | [Pubmed] | [DOI] | | | 129 |
Small molecule probes of protein aggregation |
|
| Lydia M Young,Alison E Ashcroft,Sheena E Radford | | Current Opinion in Chemical Biology. 2017; 39: 90 | | [Pubmed] | [DOI] | | | 130 |
Familial Mutations May Switch Conformational Preferences in a-Synuclein Fibrils |
|
| Liang Xu,Buyong Ma,Ruth Nussinov,Damien Thompson | | ACS Chemical Neuroscience. 2017; | | [Pubmed] | [DOI] | | | 131 |
Up-regulation of autophagy-related gene 5 (ATG5) protects dopaminergic neurons in a zebrafish model of Parkinsonæs disease |
|
| Zhan-ying Hu,Bo Chen,Jing-pu Zhang,Yuan-yuan Ma | | Journal of Biological Chemistry. 2017; 292(44): 18062 | | [Pubmed] | [DOI] | | | 132 |
Finding a new purpose for old drugs |
|
| Evan Y. Snyder | | Science. 2017; 357(6354): 869 | | [Pubmed] | [DOI] | | | 133 |
Correlation of Plasma EGF with Striatal Dopamine Transporter Availability in Healthy Subjects |
|
| Kyoungjune Pak,Seunghyeon Shin,So Jung Kim,Keunyoung Kim,Bum Soo Kim,Seong Jang Kim,In Joo Kim | | Scientific Reports. 2017; 7(1) | | [Pubmed] | [DOI] | | | 134 |
Synucleins and Gene Expression: Ramblers in a Crowd or Cops Regulating Traffic? |
|
| Alexei A. Surguchev,Andrei Surguchov | | Frontiers in Molecular Neuroscience. 2017; 10 | | [Pubmed] | [DOI] | | | 135 |
a-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinsonæs disease |
|
| Sushil K Singh,Aloke Dutta,Gyan Modi | | Future Medicinal Chemistry. 2017; 9(10): 1039 | | [Pubmed] | [DOI] | |
|
 |
|
|
|
Search Pubmed for